Amrinone administration in endotoxin shock.
This study explored the hemodynamic effects of amrinone, a phosphodiesterase inhibitor, in association with intravenous fluids, in the treatment of endotoxin shock. Mongrel dogs were anesthetized with pentobarbital and mechanically ventilated with room air. Treatment was started 30 min after slow intravenous administration of 3 mg/kg of E. coli endotoxin. In the first part of the study, ten dogs were resuscitated for 30 min with intravenous saline alone (10 ml/kg) and for the next 3 h by saline (10 ml/kg/h) and amrinone 40 micrograms/kg/min. During this latter period, arterial pressure remained stable while cardiac output significantly increased from 3.1 +/- 0.5 to 5.2 +/- 0.7 l/min (P less than 0.01), and oxygen delivery increased from 616 +/- 92 to 983 +/- 156 ml/min (P less than 0.01). Comparison with control animals revealed that amrinone infusion prevented the decrease in left ventricular stroke work and markedly increased oxygen delivery. In the second part of the study, 18 dogs were treated by saline infusion titrated to maintain pulmonary artery balloon-occluded pressure at baseline level. In ten dogs, amrinone was added 60 min after endotoxin administration at a dose of 40 micrograms/kg/min. Total amount of fluids infused averaged 87 +/- 14 ml in the amrinone-treated dogs and 64 +/- 15 ml in the control dogs (differences nonsignificant). Oxygen delivery and oxygen consumption increased significantly in the amrinone-treated dogs (from 541 +/- 36 to 1063 +/- 176 ml/min, P less than 0.01, and from 145 +/- 23 to 202 +/- 38 ml/min, P less than 0.01, respectively) but not in the control dogs. The amrinone-treated dogs had lower PaO2 and higher venous admixture than the control dogs.(ABSTRACT TRUNCATED AT 250 WORDS)
Vincent
J L
JL
Department of Intensive Care, Erasme University Hospital, Brussels, Belgium.
Domb
M
M
Van der Linden
P
P
Motte
S
S
de Boelpaepe
C
C
Contempré
B
B
Cantraine
F
F
D000676:Amrinone / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002302:Cardiac Output / Q000187:drug effects*; D003131:Combined Modality Therapy; D004285:Dogs; D004731:Endotoxins; D004926:Escherichia coli; D005440:Fluid Therapy; D007262:Infusions, Intravenous; D010101:Oxygen Consumption / Q000187:drug effects; D012772:Shock, Septic / Q000139:chemically induced / Q000628:therapy*; D013318:Stroke Volume / Q000187:drug effects
D004731:Endotoxins; D000676:Amrinone